Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
34
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
21
users have liked this narrative
12
users have commented on this narrative
27
users have followed this narrative
13 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
25
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Saudi Basic Industries
AN
AnalystLowTarget
Consensus Narrative from 13 Analysts
Tightening Environmental Rules And Oversupply Will Squeeze Margins
Key Takeaways Heightened regulation, recycling trends, and global oversupply are set to weaken demand and compress margins for SABIC's core petrochemical products. Reliance on subsidies and large capital projects increases SABIC's exposure to profitability risks and pressures shareholder returns.
View narrative
ر.س52.00
FV
19.2% overvalued
intrinsic discount
0.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
16 days ago
author updated this narrative
Merck KGaA
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten
Key Takeaways Underperformance in legacy segments, slow R&D, and overreliance on blockbusters threaten competitiveness as innovation and patent expiries reshape the market. Tightening regulation, geopolitical risks, and operational headwinds add sustained pressure on margins and revenue stability.
View narrative
€105.50
FV
6.3% overvalued
intrinsic discount
1.81%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
16 days ago
author updated this narrative
Chugai Pharmaceutical
AN
AnalystLowTarget
Consensus Narrative from 14 Analysts
Global Pricing Cuts And Pipeline Delays Will Dim Prospects
Key Takeaways Reliance on a narrow set of high-earning drugs and pipeline uncertainty increases exposure to competitive threats and potential revenue volatility. Ongoing price pressures, biosimilar competition, and major capital investments risk squeezing margins, straining cash flow, and impacting long-term growth prospects.
View narrative
JP¥6.10k
FV
1.7% overvalued
intrinsic discount
1.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
SAP
AN
AnalystLowTarget
Consensus Narrative from 26 Analysts
Eroding Pricing Power And Execution Risks Will Unsettle Prospects
Key Takeaways Intensifying competition from cloud-native and specialized SaaS solutions threatens SAP's pricing power, differentiation, and market share, reducing cross-selling potential and revenue growth. Migration to subscription cloud and rapid AI integration bring execution risks, cost pressures, and complexity, negatively impacting margins and long-term scalability.
View narrative
€217.16
FV
7.1% overvalued
intrinsic discount
10.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
16 days ago
author updated this narrative
Fennec Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Single Product Reliance Will Trigger Setbacks But Potential Remains
Key Takeaways Heavy reliance on a single drug and exposure to pricing pressure threaten margin stability and make future revenue growth dependent on successful pipeline expansion. Expansion into new demographics and regions offers growth potential, but slow adoption, regulatory hurdles, and resource limits may restrain market penetration and earnings.
View narrative
US$13.00
FV
33.4% undervalued
intrinsic discount
49.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
L.B. Foster
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Rail And Funding Risks Will Compress Margins Yet Elevate Tech
Key Takeaways Heavy dependence on government infrastructure funding and cyclical, low-margin operations introduces ongoing risk to revenue predictability and sustainable margin growth. Limited scale, R&D underinvestment, and slower global expansion may restrict competitiveness as the market shifts toward higher-tech, smart infrastructure solutions.
View narrative
US$25.00
FV
2.3% undervalued
intrinsic discount
5.97%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
Chicago Atlantic Real Estate Finance
AN
AnalystLowTarget
Consensus Narrative from 4 Analysts
Cannabis Exposure Will Pressure Margins While Opportunities Slowly Emerge
Key Takeaways Heavy dependence on cannabis lending exposes the company to sector-specific legal risks and threatens long-term credit stability if regulations shift or market conditions worsen. Intensifying competition from traditional banks and new fintech platforms could erode loan yields, margins, and sustainable earnings if the company fails to diversify.
View narrative
US$14.50
FV
0.6% undervalued
intrinsic discount
0.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
JTEKT India
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Expansion In C-EPS And CVJ Will Strengthen Future Product Portfolio
Key Takeaways Favorable policy and infrastructure developments forecast positive revenue impact, supported by localization and new export opportunities. Expansion plans and advanced product improvements aim at increased capacity and profitability through higher technological value and cost efficiency.
View narrative
₹151.00
FV
12.8% undervalued
intrinsic discount
9.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Willdan Group
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Technological Shifts And Rising Wages Will Erode Market Position
Key Takeaways Accelerating automation and slow digital adaptation threaten Willdan's core consulting model, competitiveness, and client retention. Labor cost pressures, contract dependency, and weak pricing power heighten margin risk and revenue volatility.
View narrative
US$85.00
FV
30.7% overvalued
intrinsic discount
11.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
16 days ago
author updated this narrative
Value any company in seconds
Popular companies